Evidence map›Paper›PMID 41334295›Full record

ArticleJournal of current ophthalmology

Topical Fasudil in Type 2 Retinopathy of Prematurity: A Pilot Study.

Alireza Ramezani, Niloufar Mohammadbagheri, Hamid Ahmadieh, Morteza Entezari, Mehdi Emamverdi, Hamid Safi, Bahareh Kheiri, Sare Safi, Homayoun Nikkhah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alireza RamezaniOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Niloufar MohammadbagheriOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamid AhmadiehOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Morteza EntezariOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehdi EmamverdiDoheny Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, USA.
Hamid SafiOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Bahareh KheiriOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sare SafiOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Homayoun NikkhahOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the safety and effectiveness of topical fasudil drop, as a Rho kinase (ROCK) inhibitor agent, on type 2 retinopathy of prematurity (ROP). Methods: This comparative case series included 42 eyes of 21 premature infants with type 2 ROP. One eye of each patient was randomly assigned to receive a fasudil eye drop of 0.5% twice a day. The other eye received artificial tear drops twice a day as a control. The administration began at the time of prethreshold ROP diagnosis until 45 weeks of postmenstrual age. Funduscopic examination was performed weekly until complete retinal vascularization or progression into type 1 ROP. The extent of the retinal avascular area or progression into type 1 prethreshold ROP was compared between the two eyes of each infant. The influence of associated systemic conditions on the process of angiogenesis was also evaluated. Results: In 5 (23.8%) premature infants, reduction of the avascular zone area was observed in eyes treated with fasudil drop compared to the other eye ( Conclusion: Topical 0.5% fasudil was safe, but showed no statistically significant benefit in reducing the avascular zone or preventing progression to type 1 ROP in this pilot study.

Indexed as

Retinal angiogenesisRetinopathy of prematurityTopical fasudil

Identifiers

PMID41334295
PMCPMC12668648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.